Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction (HFpEF) regardless of diuretic use, according to late-breaking research presented at Heart Failure 2024
The anti-obesity drug semaglutide may lower the risk of death from COVID-19, cardiovascular disease, and all causes, according to a randomized controlled trial published late last week in the Journal of the American College of Cardiology ( JACC )
In Hallandale Beach clinics providing semaglutide, our healthcare providers can guide you to the option that best aligns with your lifestyle
Medical or nutritional information on the mySugr website is not intended to replace professional medical advice, diagnosis or treatment
If currently deferred due to active side effects or recent treatment initiation, you may become eligible once: You have been on a stable Wegovy dose for several months without significant adverse effects Your weight and overall health meet donation criteria (minimum weight of 50 kg, stable blood pressure, good venous access) Any obesity-related comorbidities are well-controlled Maintain contact with your local donation centre and ask about reassessment timelines
